Cargando…
TSPO Ligands PK11195 and Midazolam Reduce NLRP3 Inflammasome Activation and Proinflammatory Cytokine Release in BV-2 Cells
Neuroinflammation related to microglial activation plays an important role in neurodegenerative diseases. Translocator protein 18 kDa (TSPO), a biomarker of reactive gliosis, its ligands can reduce neuroinflammation and can be used to treat neurodegenerative diseases. Therefore, we explored whether...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759202/ https://www.ncbi.nlm.nih.gov/pubmed/33362467 http://dx.doi.org/10.3389/fncel.2020.544431 |
_version_ | 1783627082137337856 |
---|---|
author | Feng, Hao Liu, Yongxin Zhang, Rui Liang, Yingxia Sun, Lina Lan, Nannan Ma, Baoyu |
author_facet | Feng, Hao Liu, Yongxin Zhang, Rui Liang, Yingxia Sun, Lina Lan, Nannan Ma, Baoyu |
author_sort | Feng, Hao |
collection | PubMed |
description | Neuroinflammation related to microglial activation plays an important role in neurodegenerative diseases. Translocator protein 18 kDa (TSPO), a biomarker of reactive gliosis, its ligands can reduce neuroinflammation and can be used to treat neurodegenerative diseases. Therefore, we explored whether TSPO ligands exert an anti-inflammatory effect by affecting the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome, thereby inhibiting the release of inflammatory cytokines in microglial cells. In the present study, BV-2 cells were exposed to lipopolysaccharide (LPS) for 6 h to induce an inflammatory response. We found that the levels of reactive oxygen species (ROS), NLRP3 inflammasome, interleukin-1β (IL-1β), and interleukin-18 (IL-18) were significantly increased. However, pretreatment with TSPO ligands inhibited BV-2 microglial and NLRP3 inflammasome activation and significantly reduced the levels of ROS, IL-1β, and IL-18. Furthermore, a combination of LPS and ATP was used to activate the NLRP3 inflammasome. Both pretreatment and post-treatment with TSPO ligand can downregulate the activation of NLRP3 inflammasome and IL-1β expression. Finally, we found that TSPO was involved in the regulation of NLRP3 inflammasome with TSPO ligands treatment in TSPO knockdown BV2 cells. Collectively, these results indicate that TSPO ligands are promising targets to control microglial reactivity and neuroinflammatory diseases. |
format | Online Article Text |
id | pubmed-7759202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77592022020-12-25 TSPO Ligands PK11195 and Midazolam Reduce NLRP3 Inflammasome Activation and Proinflammatory Cytokine Release in BV-2 Cells Feng, Hao Liu, Yongxin Zhang, Rui Liang, Yingxia Sun, Lina Lan, Nannan Ma, Baoyu Front Cell Neurosci Cellular Neuroscience Neuroinflammation related to microglial activation plays an important role in neurodegenerative diseases. Translocator protein 18 kDa (TSPO), a biomarker of reactive gliosis, its ligands can reduce neuroinflammation and can be used to treat neurodegenerative diseases. Therefore, we explored whether TSPO ligands exert an anti-inflammatory effect by affecting the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome, thereby inhibiting the release of inflammatory cytokines in microglial cells. In the present study, BV-2 cells were exposed to lipopolysaccharide (LPS) for 6 h to induce an inflammatory response. We found that the levels of reactive oxygen species (ROS), NLRP3 inflammasome, interleukin-1β (IL-1β), and interleukin-18 (IL-18) were significantly increased. However, pretreatment with TSPO ligands inhibited BV-2 microglial and NLRP3 inflammasome activation and significantly reduced the levels of ROS, IL-1β, and IL-18. Furthermore, a combination of LPS and ATP was used to activate the NLRP3 inflammasome. Both pretreatment and post-treatment with TSPO ligand can downregulate the activation of NLRP3 inflammasome and IL-1β expression. Finally, we found that TSPO was involved in the regulation of NLRP3 inflammasome with TSPO ligands treatment in TSPO knockdown BV2 cells. Collectively, these results indicate that TSPO ligands are promising targets to control microglial reactivity and neuroinflammatory diseases. Frontiers Media S.A. 2020-12-10 /pmc/articles/PMC7759202/ /pubmed/33362467 http://dx.doi.org/10.3389/fncel.2020.544431 Text en Copyright © 2020 Feng, Liu, Zhang, Liang, Sun, Lan and Ma. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular Neuroscience Feng, Hao Liu, Yongxin Zhang, Rui Liang, Yingxia Sun, Lina Lan, Nannan Ma, Baoyu TSPO Ligands PK11195 and Midazolam Reduce NLRP3 Inflammasome Activation and Proinflammatory Cytokine Release in BV-2 Cells |
title | TSPO Ligands PK11195 and Midazolam Reduce NLRP3 Inflammasome Activation and Proinflammatory Cytokine Release in BV-2 Cells |
title_full | TSPO Ligands PK11195 and Midazolam Reduce NLRP3 Inflammasome Activation and Proinflammatory Cytokine Release in BV-2 Cells |
title_fullStr | TSPO Ligands PK11195 and Midazolam Reduce NLRP3 Inflammasome Activation and Proinflammatory Cytokine Release in BV-2 Cells |
title_full_unstemmed | TSPO Ligands PK11195 and Midazolam Reduce NLRP3 Inflammasome Activation and Proinflammatory Cytokine Release in BV-2 Cells |
title_short | TSPO Ligands PK11195 and Midazolam Reduce NLRP3 Inflammasome Activation and Proinflammatory Cytokine Release in BV-2 Cells |
title_sort | tspo ligands pk11195 and midazolam reduce nlrp3 inflammasome activation and proinflammatory cytokine release in bv-2 cells |
topic | Cellular Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759202/ https://www.ncbi.nlm.nih.gov/pubmed/33362467 http://dx.doi.org/10.3389/fncel.2020.544431 |
work_keys_str_mv | AT fenghao tspoligandspk11195andmidazolamreducenlrp3inflammasomeactivationandproinflammatorycytokinereleaseinbv2cells AT liuyongxin tspoligandspk11195andmidazolamreducenlrp3inflammasomeactivationandproinflammatorycytokinereleaseinbv2cells AT zhangrui tspoligandspk11195andmidazolamreducenlrp3inflammasomeactivationandproinflammatorycytokinereleaseinbv2cells AT liangyingxia tspoligandspk11195andmidazolamreducenlrp3inflammasomeactivationandproinflammatorycytokinereleaseinbv2cells AT sunlina tspoligandspk11195andmidazolamreducenlrp3inflammasomeactivationandproinflammatorycytokinereleaseinbv2cells AT lannannan tspoligandspk11195andmidazolamreducenlrp3inflammasomeactivationandproinflammatorycytokinereleaseinbv2cells AT mabaoyu tspoligandspk11195andmidazolamreducenlrp3inflammasomeactivationandproinflammatorycytokinereleaseinbv2cells |